LTAS
KRYS icon

Linden Thomas Advisory Services’s Krystal Biotech KRYS Stock Holding History

Linden Thomas Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Sell
1,064
-8
-0.7% -$2.39K 0.03% 431
2026
Q1 		$277K Buy
+1,072
New +$285K 0.03% 463

Other funds holding KRYS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Linden Thomas Advisory Services's KRYS Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Krystal Biotech (KRYS) stake by 0.75% in Q2 2026, selling an estimated $2.39K and leaving 1,064 shares worth $395K. The position accounts for 0.03% of the portfolio, ranked #431.

Linden Thomas Advisory Services first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Linden Thomas Advisory Services held 1,064 shares of Krystal Biotech worth $395K as of Q2 2026.
  • Linden Thomas Advisory Services sold 8 Krystal Biotech shares in Q2 2026, an estimated $2.39K.
  • Krystal Biotech made up 0.03% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #431 holding.
  • Linden Thomas Advisory Services first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.